Taltz Results In Spondyloarthritis Add To Lilly Franchise Hopes
Executive Summary
Taltz has sailed through the latest trial in Lilly’s COAST program, in non-radiographic axial spondyloarthritis, but choppy waters may be ahead; meanwhile, Lilly signs an immunology deal with Avidity Biosciences.
You may also be interested in...
Novartis Eyes Fourth Approval For Cosentyx
As Novartis files Cosentyx for non-radiographic axial spondyloarthritis, it is becoming increasingly clear that psoriasis will not be the blockbuster's revenue growth driver going forward.
Keeping Track: CDER Ties Monthly Novel Approval Record With Nourianz Green Light
The latest drug development news and highlights from our US FDA Performance Tracker.
Lilly's Taltz Approved For AS As New Guidelines Keep TNF Inhibitors In Front Line
VP Rebecca Morison said the ankylosing spondylitis indication adds more evidence of Taltz's benefits. She noted Lilly believes there should be fewer steps before AS patients access IL-17 inhibitors.